A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Sponsor
Novo Nordisk A/S
Study ID
NCT03172494
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Insulin degludec/liraglutide — DRUG
    Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
  • Insulin degludec — DRUG
    Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
  • Liraglutide — DRUG
    Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

Study Details

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Key Dates

Start date
May 26, 2017
Status verified
Nov 2022
Primary completion
Jun 14, 2019
Completion
Jul 13, 2019

Study Design

Enrollment
720 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Insulin degludec/liraglutide
  • Active Comparator: Insulin degludec
  • Active Comparator: Liraglutide

Primary Outcome Measure

Change in HbA1c [ Time Frame: Week 0, week 26 ]

Related Studies